Physician profile
Eric M Ward
NPI 1699703041
$5,001.46
in general payments reported to CMS, 2019-2025
30 companies · $913 in 2025
The $913 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $407 · 2021: $905 · 2022: $481 · 2023: $456 · 2024: $730 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,099.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,102.44 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $467.19 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $465.70 | 2019-2025 | Entyvio |
| Pfizer INC. | $240.90 | 2019-2025 | |
| Madrigal Pharmaceuticals | $174.67 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.94 | 2019-2022 | |
| Boston Scientific Corporation | $136.85 | 2021-2024 | |
| Evoke Pharma, INC. | $121.93 | 2021-2024 | Gimoti |
| Intercept Pharmaceuticals, INC. | $116.76 | 2019-2022 | |
| Braintree Laboratories, INC. | $110.20 | 2019-2024 | Sutab |
| Genzyme Corporation | $107.80 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $85.66 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $74.94 | 2019-2023 | Linzess |
| Gilead Sciences, INC. | $70.39 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $63.29 | 2024-2025 | Zenpep |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $60.82 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $60.35 | 2021-2022 | |
| Medtronic, INC. | $56.78 | 2025 | Gi Genius |
| Redhill Biopharma INC. | $50.32 | 2021 | |
| Merck Sharp & Dohme LLC | $46.36 | 2019-2022 | |
| Ucb, INC. | $44.83 | 2019 | |
| Daiichi Sankyo INC. | $44.64 | 2019-2023 | Injectafer |
| Enterra Medical, INC. | $27.94 | 2025 | |
| Phathom Pharmaceuticals, INC. | $24.01 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.93 | 2023 | Cyltezo |
| Alfasigma USA, INC. | $15.24 | 2020 | |
| Dova Pharmaceuticals | $13.99 | 2019 | |
| Shire North American Group INC | $13.91 | 2019 | |
| Lilly USA, LLC | $13.30 | 2024 | Omvoh |
| Mauna Kea Technologies, INC. | $10.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.